Research
Hormonal
GLP-1 receptor agonists reduce major adverse cardiac events and cardiovascular mortality in patients with Type 2 Diabetes, particularly those without pre-existing heart failure.
If you have Type 2 Diabetes, GLP-1 drugs (like Ozempic or Victoza) are highly recommended for heart protection. They significantly lower the risk of heart attacks and death. If you already have heart failure, they still help prevent new cases but may not stop existing failure from worsening as effectively.
GoodQualifiesHIGH confidence
Liraglutide, semaglutide, and albiglutide have been associated with a reduced risk of major adverse cardiac events... A recent meta-analysis... suggested that GLP-1 RAs might help prevent new-onset HF in the diabetic population. However, in patients with pre-existing HF, these drugs did not significantly reduce the risk of HF exacerbation or mortality
Why this rating
Based on meta-analyses of randomized controlled trials.
Source
Advances in the Insulin–Heart Axis: Current Therapies and Future Directions
Alfredo Caturano et al. · International Journal of Molecular Sciences · 2024
DOI 10.3390/ijms251810173
narrative_reviewCited 17×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle modifications, specifically Mediterranean diet and moderate aerobic exercise, are the cornerstone for managing insulin resistance and improving cardiovascular outcomes.Strong
- SGLT2 inhibitors reduce cardiovascular mortality and heart failure hospitalization in insulin-resistant patients by promoting ketone body production and reducing sympathetic overdrive.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →